国药集团一致药业股份有限公司 2015 年第一季度报告全文
China National Accord Medicines Corporation Ltd.
First Quarterly Report 2015
April 2015
1
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Section I. Important Notes
Board of Directors and the Supervisory Committee of China National Accord Medicines
Corporation Ltd. (hereinafter referred to as the Company) and its directors, supervisors and
senior executives should guarantee the reality, accuracy and completion of the quarterly
report, there are no any fictitious statements, misleading statements or important omissions
carried in this report, and shall take legal responsibilities, individual and/or joint.
All Directors are attended the Board Meeting for Quarterly Report deliberation.
Yan Zhigang, person in charge of the Company, Wei Pingxiao, person in charger of
accounting works and Zhou Feifei, person in charger of accounting organ (accounting officer)
hereby confirm that the Financial Report of this Quarterly Report is authentic, accurate and
complete.
2
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Section II. Main financial data and changes of shareholders
I. Main accounting data and financial indexes
Whether it has retroactive adjustment or re-statement on previous accounting data for accounting policy changed and accounting
error correction or not
□ Yes √No
Changes of this period over
Current Period Same period of last year
same period of last year
Operating income (RMB) 6,261,714,700.23 5,533,524,159.08 13.16%
Net profit attributable to shareholders of
197,026,237.82 167,818,387.39 17.40%
the listed company(RMB)
Net profit attributable to shareholders of
the listed company after deducting 192,315,542.07 165,006,263.57 16.55%
non-recurring gains and losses(RMB)
Net cash flow arising from operating
-425,683,165.96
activities(RMB) 182,179,606.70 142.80%
Basic earnings per share (RMB/Share) 0.543 0.582 -6.70%
Diluted earnings per share (RMB/Share) 0.543 0.582 -6.70%
Weighted average ROE 4.05% 7.21% -3.16%
Changes of this period-end
At the end of the reporting
At the end of last year over same period-end of last
period
year
Total assets (RMB) 13,399,261,901.35 12,828,941,540.90 4.45%
Net assets attributable to shareholder of
4,961,634,059.91 4,764,607,822.09 4.14%
listed company (RMB)
Items of non-recurring gains and losses
√ Applicable □ Not applicable
In RMB
Amount from year-begin to
Item Note
period-end
Gains/losses from the disposal of non-current asset (including the
-118,671.15
write-off that accrued for impairment of assets)
Governmental subsidy reckoned into current gains/losses (not Mainly due to follow money
including the subsidy enjoyed in quota or ration according to 5,091,842.57 received as: one million Yuan of
national standards, which are closely relevant to enterprise’s loan interest subsidy received
3
国药集团一致药业股份有限公司 2015 年第一季度报告全文
business) from Development and Finance
Bureau of Longhua New District
and Economic Services Bureau
by subsidiary of the Company,
the 0.9 million Yuan grants for
cefdinir and Cefaclor Suspension
project received from the Group,
the 674,600 Yuan of demolition
resettlement compensation for
old town received and 400000
Yuan special award for the
taxation; the patent award 300000
Yuan for year of 2013 received
from Shenzhen Market
Supervisory Authority, special
supporting fund 229000 Yuan for
the engineering lab of new-type
Cephalosporin, the 209600 Yuan
of the modern logistics public
information platform of the third
party, the special supporting
fund205300 Yuan of R&D
manufacture base for the drugs
etc.
Reversal of impairment reserve for account receivable with
8,430.00
separate impairment testing
Other non-operating income and expenditure except for the
663,591.41
aforementioned items
Less: impact on income tax 934,220.09
Impact on minority shareholders’ equity (post-tax) 276.99
Total 4,710,695.75 --
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for Companies
Offering Their Securities to the Public --- Extraordinary Profit/loss, and the items defined as recurring profit (gain)/loss according to
the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their
Securities to the Public --- Extraordinary Profit/loss, explain reasons
□ Applicable √ Not applicable
In reporting period, the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of
extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to
the Public --- Extraordinary Profit/loss
II. Total number of shareholders at the end of this report period and top ten shareholders
1. Total number of common shareholders at the end of this report period and top ten common shareholders
In shares
4
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Total common shareholders
14,356
at the end of report period
Top ten common shareholders
Amount of Number of share pledged/frozen
Shareholder’s Nature of Proportion of Amount of shares
restricted shares
name shareholder shares held held State of share Amount
held
Sinopharm State-owned
51.00% 184,942,291 74,482,543
Group Co., Ltd. legal person
National Social Domestic non
Security Fund state-owned legal 2.12% 7,700,000
116 combination person
National Social Domestic non
Security Fund state-owned legal 2.01% 7,298,555
106 combination person
HTHK/CMG
FSGUFP-CMG
Foreign
FIRST STATE 1.94% 7,032,720
Corporation
CHINA
GROWTH FD
BOC—Harvest
Domestic non
theme selected
state-owned 1.18% 4,274,694
mix securities
Corporation
investment fund
New China Life
Insurance Co.,
Ltd. – Bonus – Domestic non
Individual state-owned 1.16% 4,199,772
bonuses - Corporation
-018L-FH002
Shen
BOC-Harvest
Domestic non
research selected
state-owned 0.96% 3,489,967
stock securities
Corporation
investment fund
China Merchants
Foreign
Securities (HK) 0.94% 3,403,702
Corporation
Co., Limited
GUOTAI
JUNAN Foreign
0.92% 3,346,576
SECURITIES(H Corporation
ONGKONG)
5
国药集团一致药业股份有限公司 2015 年第一季度报告全文
LIMITED
China Life
Insurance Co.,
Ltd. – tradition – Domestic non
general insurance state-owned 0.83% 3,000,000
products - Corporation
005L-CT001
Shen
Top ten common shareholders with unrestricted shares held
Type of shares
Shareholder’s name Amount of unrestricted shares held
Type Amount
RMB ordinary
Sinopharm Holding Co., Ltd. 110,459,748 110,459,748
shares
National Council for Social Security RMB ordinary
7,700,000 7,700,000
Fund-116 shares
National Council for Social Security RMB ordinary
7,298,555 7,298,555
Fund-106 shares
HTHK/CMG FSGUFP-CMG Domestically
FIRST STATE CHINA GROWTH 7,032,720 listed foreign 7,032,720
FD shares
BOC—Harvest theme selected mix RMB ordinary
4,274,694 4,274,694
securities investment fund shares
New China Life Insurance Co., Ltd.
RMB ordinary
– Bonus – Individual bonuses - 4,199,772 4,199,772
shares
-018L-FH002 Shen
BOC-Harvest research selected RMB ordinary
3,489,967 3,489,967
stock securities investment fund shares
Domestically
China Merchants Securities (HK)
3,403,702 listed foreign 3,403,702
Co., Limited
shares
GUOTAI JUNAN Domestically
SECURITIES(HONGKONG) 3,346,576 listed foreign 3,346,576
LIMITED shares
China Life Insurance Co., Ltd. –
RMB ordinary
tradition – general insurance 3,000,000 3,000,000
shares
products - 005L-CT001 Shen
BOC—Harvest theme selected mix securities investment fund and BOC-Harvest research
Explanation on associated selected stock securities investment fund have the same custodian as Harvest Fund
relationship among the aforesaid Management Co., Ltd.; it is unknown that there exists no associated relationship or belongs to
shareholders the consistent actionist among the other tradable shareholders regulated by the Management
Measure of Information Disclosure on Change of Shareholding for Listed Companies.
6
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement
dealing in reporting period
□ Yes √ No
The top ten common shareholders or top ten common shareholders with un-restrict shares held of the Company have no buy-back
agreement dealing in reporting period.
2. Total shareholders with preferred stock held at Period-end and shares held by top ten shareholders with
preferred stock held
□ Applicable √ Not applicable
7
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Section III. Significant Events
I. Particulars about material changes in items of main accounting statement and financial
index and explanations of reasons
√Applicable □Not applicable
1. Other account receivables: increased 10.45 million Yuan over that of balance at period-begin with growth rate of 36.58%, mainly
because the increase of housing lease, deposit, margin and etc. in the Period;
2. Other current assets: decreased 27.86 million Yuan over that of balance at period-begin with growth rate of -69.13%, mainly
because the retained VAT decreased in the Period;
3. Short-term loans: increased 494.71 million Yuan over that of balance at period-begin with growth rate of 32.59%, mainly because
supply chain financing increased in the Period;
4. Account received in advance: decreased 22.77 million Yuan over that of balance at period-begin with growth rate of -56.45%,
mainly because the account paid in advance for the goods from merchants declined in the Period;
5. Wages payable: decreased 69.16 million Yuan over that of balance at period-begin with growth rate of -40.22%, mainly because
the remuneration, accrual last year, has distributed in this Period;
6. Tax payable: increased 3,414 Yuan over that of balance at period-begin with growth rate of 44.09%, mainly because provision of
enterprise income tax increased in the Period;
7. Interest payable: increased 4.03 million Yuan over that of balance at period-begin with growth rate of 60.51%, mainly because the
scale of financing goes up in the Period;
8. Non-current liability due within one year: increased 1.26 million Yuan y-o-y with growth rate of 31.50%, mainly because the
member points due within one year increased in the Period;
9. Financial expenses: decreased 20.11 million Yuan y-o-y with growth rate of -42.55%, mainly because of the decrease in loans in
the Period;
10. Assets impairment loss: increased 1.4 million Yuan y-o-y with growth rate of 56.78%, mainly because the inventory falling price
reserves accrual in the Period increased;
11. Non-operation revenue: increased 2.17 million Yuan y-o-y with growth rate of 57.08%, mainly because the government subsidy
received in the Period increased on a y-o-y basis;
12. Non-operation expenditure-losses from disposal of non-current assets: increased 8400 Yuan y-o-y with growth rate of 222.84%,
mainly because loss of the fixed assets disposed as vehicles in the Period increased y-o-y;
13. Income tax expenses: increased 12.92 million Yuan y-o-y with growth rate of 30.60%, mainly because profitability improved and
income tax expense increased in the Period;
14. Cash received with other operation activities concerned: increased 14.84 million Yuan y-o-y with growth rate of 103.26%, mainly
because the margin received government compensation for removal and government grants received in the Period are increase on a
y-o-y basis;
15. Net cash flow from operation activity: increased 608 million Yuan y-o-y with growth rate of142.80%, mainly because the
account paid for procurement and vary taxes paid in the Period decreased y-o-y;
16. Net cash received from disposal of fixed assets, intangible assets and other long-term assets: decreased 0.23 million Yuan y-o-y
with growth rate of -91.16%, mainly because income from disposal of fixed assets in the Period decreased y-o-y;
17. Cash received with other investment activities: decreased 5.08 million Yuan y-o-y with growth rate of -100%, mainly because the
8
国药集团一致药业股份有限公司 2015 年第一季度报告全文
monetary fund owned by Sinopharm Holding Shantou on purchasing day, the subsidiary newly acquired in last Period, was listed in
the item, and no such account occurred in the Period;
18. Cash paid with other investment activities concerned: increased 2,520,000 Yuan y-o-y with growth rate of 100%,mainly because
money for 10% equity of Sinopharm Holding Zhuhai are paid in the Period while no such business occurred at same period of last
year;
19. Cash received by investors: decreased 1.94 billion Yuan y-o-y with growth rate of -99.93%, mainly because amount from private
placement was received in the same period of last year, and no such business occurred in the Period;
20. Cash inflows from minority investment in subsidiaries: increased 1.47 million Yuan y-o-y with growth rate of 100%, mainly
because the enterprise newly established in the Period received investment from minority’s while there is no such business occurred
at same period last year;
21. Cash received from loan: decreased 186 million Yuan y-o-y with growth rate of -100%, mainly because loans in the Period
decreased y-o-y;
22. Cash paid for debt settlement: decreased 383 million Yuan y-o-y with growth rate of -85.73%, mainly because loans payment in
the Period decreased y-o-y;
23. Cash paid for distribution of dividend or profit or cash payments for interests: decreased 23.27 million Yuan y-o-y with growth
rate of -47.94%, mainly because the loans interest paid in the Period decreased y-o-y;
24. Cash paid with other financing activities concerned: increased 7.94 million Yuan y-o-y with growth rate of37.68%, mainly
because the repay for supply chain financing in the Period increased y-o-y;
25. Net cash flow from financing activity: decreased 1.729billion Yuan y-o-y with growth rate of -107.24%, mainly because amount
from private placement was received in the same period of last year, and no such business occurred in the Period;
26. Influence on cash and cash equivalent from exchange rate movement: increased 4,600 Yuan y-o-y with growth rate of 99.50%,
mainly because foreign currency held increased.
II. Analysis and explanation of significant events and their influence and solutions
□ Applicable √ Not applicable
III. Commitments from the Company or shareholders (with over 5% shares held) in or
occurred in the previous period but continued to reporting period
√Applicable □Not applicable
Commitmen Commitment
Commitments Accepter Contents Implementation
t time period
Share Merger
Reform
As a large pharmaceutical commercial enterprise
whose business involves pharmaceutical wholesale
Commitments
and retail, Sinopharm Holding may overlap with the Normally
in report of Sinopharm Long-term
Company in geographical segmentation during its 2005-06-21 implement
acquisition or Holding effective
future business development. To avoid the potential
equity change
peer competition brought by such geographical
overlap, Sinopharm Holding undertakes that, upon
9
国药集团一致药业股份有限公司 2015 年第一季度报告全文
the transfer of shares of Sinopharm Holding
Guangzhou it held to Accord Pharma, ―1. it will not
newly-establish or broaden within Guangdong any
business operation that actually compete with that
of Accord Pharma, or set up any new subsidiaries or
subordinate enterprises who engage in such
business. 2. it will enter into business delineation
with Accord Pharma and Sinopharm Holding
Guangzhou, thereby giving the three parties clear
geographical areas to carry out pharmaceutical
wholesale and retail businesses, so as to avoid
potential peer competition. Apart from above,
Sinopharm Holding will no longer newly-establish
any enterprise that may compete with Accord
Pharma in the production and R&D of
pharmaceutical products.‖
Commitments
in assets
reorganization
Sinopharm Holding has undertaken in the Letter of
Undertaking from Sinopharm Group Co. Ltd. on
Avoiding Peer Competition that, ―I. the Company
and the enterprises it wholly-owns, controls or has
de facto control over (excluding Sinopharm Accord
and its controlled enterprises, similarly hereinafter)
do not exist any business or operation that would
Controlling
constitute substantive peer competition with
shareholder is
Sinopharm Accord and its controlled enterprises. II.
implement in real
the Company and the enterprises it wholly-owns,
earnest,
controls or has de facto control over will not engage
Commitments Sinopharm
in, participate in or carry out in Guangdong and
make in initial Sinopharm Long-term Accord will
Guangxi any business or activities that would 2013-09-05
public offering Holding effective actively urged the
constitute substantive competition with the
or re-financing controlling
pharmaceutical commercial businesses of
shareholder and
Sinopharm Accord. III. the Company and the
actual controller
enterprises it wholly-owns, controls or has de facto
to fulfill
control over will not engage in, participate in or
commitments
carry out any business or activities that would
constitute substantive competition with the
pharmaceutical industrial businesses of Sinopharm
Accord. IV. the Company will not make use of its
control over Sinopharm Accord to damage the legal
interests of Sinopharm Accord and other
shareholders (especially minority shareholders).
10
国药集团一致药业股份有限公司 2015 年第一季度报告全文
The Letter of Undertaking takes effect since the
date of issue and will remain effective during the
entire period when the Company has been the
controlling shareholder or connected party of
Sinopharm Accord. During the validity of the
Undertaking, the Company will indemnify in time
Sinopharm Accord from any loss which may arise
out of the Company’s violation of the Undertaking.‖
Sinopharm Holding has undertaken in the Letter of
Undertaking from Sinopharm Group Co. Ltd. on
Standardization of the Connected Transactions with
China National Accord Medicines Corporation Ltd.
that, ―I. during the period when the Company takes
control over Sinopharm Accord, the Company and
the companies or enterprises it directly or indirectly
controls (hereinafter referred to as ―Connected
Party‖) will strictly standardize the connected
transactions with Sinopharm Accord and its
controlled enterprises. II. for those connected
transactions beyond avoidance or out of reasonable
causes, the Company and Connected Party will Controlling
enter into standardized connected transaction shareholder is
agreement with Sinopharm Accord according to implement in real
law. Sinopharm Accord will perform approval earnest,
procedure according to relevant laws, rules and Sinopharm
Sinopharm regulations, other standardization documents and its Long-term Accord will
2013-09-05
Holding constitutional documents, and fulfill its obligation effective actively urged the
to disclose information on connected transactions. controlling
III. for those connected transactions beyond shareholder and
avoidance or out of reasonable causes, the actual controller
Company and Connected Party will determine the to fulfill
prices of connected transactions based on the prices commitments
of same or similar transactions entered into by
independent third parties of no connection while
following the principles of open, fair and just to
ensure the fairness. IV. when the board or
shareholders’ meeting of Sinopharm Accord votes
on the relevant connected transactions involving the
Company and other enterprises it controls, the
Company will perform obligations including that
necessary interested directors and shareholders shall
be abstained from voting according to relevant
regulations, and follow the legal procedures for
approval of connected transactions and fulfill its
11
国药集团一致药业股份有限公司 2015 年第一季度报告全文
information disclosure obligation. V. the Company
guarantees to attend shareholders’ meeting
according to the constitutional documents of
Sinopharm Accord, exercise its corresponding
rights and assumed its corresponding obligations in
an equitable manner, not to take advantage of its
standing as controlling shareholder to seek unjust
interests, or to use connected transactions to
illegally transfer capital or profit out of Sinopharm
Accord, or to prejudice the legal interests of
Sinopharm Accord and other shareholders
(especially minority shareholders). VI. the Letter of
Undertaking takes effect since the date of issue and
will remain effective during the entire period when
the Company has been the controlling shareholder
or connected party of Sinopharm Accord. During
the validity of the Undertaking, the Company will
indemnify in time Sinopharm Accord from any loss
that may arise out of the Company’s violation of the
Undertaking.‖
‖Sinopharm Group has undertaken in the Letter of
Undertaking from China National Pharmaceutical
Group Corporation on Avoiding the Peer
Competition with China National Accord Medicines
Corporation Ltd. that, ―I. in the coming five years,
Sinopharm Group intends to take appropriate
measures including replacement or acquisition of Actual controller
assets or equity reorganization to solve the problem is implement in
of peer competition between Weiqida and real earnest,
Sinopharm Accord. II. apart from the matters Sinopharm
disclosed in the past and in the Letter of Accord will
Sinopharm Long-term
Undertaking, the Company and the enterprises it 2013-10-16 actively urged the
Group effective
wholly-owns, controls or has de facto control over controlling
(excluding Sinopharm Accord and its controlled shareholder and
enterprises, similarly hereinafter) do not directly actual controller
engage in, participate in or carry out within the PRC to fulfill
any business or activities that would constitute commitments
substantive competition with the production and
operation of Sinopharm Accord. The relative
undertakings in respect of avoiding peer
competition given by the Company in the past
remain valid. III. the Company will not take
advantage of its control over Sinopharm Accord to
12
国药集团一致药业股份有限公司 2015 年第一季度报告全文
damage the legal interests of Sinopharm Accord
and other shareholders (especially minority
shareholders). IV. the Letter of Undertaking takes
effect since the date of issue and will remain
effective during the entire period when the
Company has been the de facto controller or
connected party of Sinopharm Accord.‖
Sinopharm Group has undertaken in the Letter of
Undertaking from China National Pharmaceutical
Group Corporation on Standardization of the
Connected Transactions with China National
Accord Medicines Corporation Ltd that, ―I.
during the period when the Company takes control
over Sinopharm Accord, the Company and the
companies or enterprises it directly or indirectly
controls (hereinafter referred to as ―Connected
Party‖) will strictly standardize the connected
transactions with Sinopharm Accord and its
controlled enterprises. II. for those connected
transactions beyond avoidance or out of reasonable
causes, the Company and Connected Party will Actual controller
enter into standardized connected transaction is implement in
agreement with Sinopharm Accord according to real earnest,
law. Sinopharm Accord will perform approval Sinopharm
procedure according to relevant laws, rules and Accord will
Sinopharm Long-term
regulations, other standardization documents and its 2013-09-22 actively urged the
Group effective
constitutional documents, and fulfill its obligation controlling
to disclose information on connected transactions. shareholder and
III. for those connected transactions beyond actual controller
avoidance or out of reasonable causes, the to fulfill
Company and Connected Party will determine the commitments
prices of connected transactions based on the prices
of same or similar transactions entered into by
independent third parties of no connection while
following the principles of open, fair and just to
ensure the fairness. IV. when the board or
shareholders’ meeting of Sinopharm Accord votes
on the relevant connected transactions involving the
Company and other enterprises it controls, the
Company will perform obligations including that
necessary interested directors and shareholders shall
be abstained from voting according to relevant
regulations, and follow the legal procedures for
approval of connected transactions and fulfill its
13
国药集团一致药业股份有限公司 2015 年第一季度报告全文
information disclosure obligation. V. the Company
guarantees not to take advantage of its standing as
actual controller to seek unjust interests, or to use
connected transactions to illegally transfer capital or
profit out of Sinopharm Accord, or to prejudice the
legal interests of Sinopharm Accord and other
shareholders (especially minority
shareholders).‖VI. the Letter of Undertaking takes
effect since the date of issue and will remain
effective during the entire period when the
Company has been the actual controller or
connected party of Sinopharm Accord.
Other
commitments
to minority
shareholders
of the
Company
Completed on
Yes
time or not
IV. Predict of the business performance from January to June 2015
Warnings and reasons of the predict that the cumulative net profit from the begin of the year to the end of next report period may be
loss or have great changes comparing with the same period of last year
□Applicable √Not applicable
V. Securities Investment
□ Applicable √ Not applicable
No security investment in the Period.
VI. Explanation on equity of other listed company held
□ Applicable √ Not applicable
No equity of other listed company held in Period-end.
VII. Derivative investment
□ Applicable √ Not applicable
No derivative investment in the Period.
VIII. Registration form for receiving research, communication and interview in the report period
□ Applicable √ Not applicable
No registration form for receiving research, communication or interview in the Period.
14
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Section IV. Financial Statement
I. Financial statement
1. Consolidate balance sheet
Prepared by China National Accord Medicines Corporation Ltd.
2015-03-31
In RMB
Item Balance at period-end Balance at period-begin
Current assets:
Monetary funds 874,682,834.63 867,562,115.54
Settlement provisions
Capital lent
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes receivable 770,803,147.42 618,995,440.09
Accounts receivable 7,571,256,086.70 7,018,312,673.19
Accounts paid in advance 111,773,033.33 96,043,154.40
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance
receivable
Interest receivable
Dividend receivable
Other receivables 39,027,837.66 28,574,927.90
Purchase restituted finance asset
Inventories 2,171,496,461.86 2,322,333,262.87
Divided into assets held for sale
Non-current asset due within one
year
Other current assets 12,444,236.68 40,308,591.47
Total current assets 11,551,483,638.28 10,992,130,165.46
Non-current assets:
15
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Loans and payments on behalf
Finance asset available for sales
Held-to-maturity investment
Long-term account receivable
Long-term equity investment 170,314,693.96 157,604,846.85
Investment property 70,116,287.93 73,836,850.51
Fixed assets 735,073,467.01 745,557,829.35
Construction in progress 349,235,832.66 330,218,696.56
Engineering material
Disposal of fixed asset
Productive biological asset
Oil and gas asset
Intangible assets 143,277,041.55 144,383,753.87
Expense on Research and
5,619,315.47 5,619,315.47
Development
Goodwill 79,378,833.15 79,378,833.15
Long-term expenses to be
37,903,104.97 39,154,232.03
apportioned
Deferred income tax asset 86,063,967.10 85,146,479.50
Other non-current asset 170,795,719.27 175,910,538.15
Total non-current asset 1,847,778,263.07 1,836,811,375.44
Total assets 13,399,261,901.35 12,828,941,540.90
Current liabilities:
Short-term loans 2,012,664,966.38 1,517,954,528.88
Loan from central bank
Absorbing deposit and interbank
deposit
Capital borrowed
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes payable 1,525,344,836.15 1,468,166,640.64
Accounts payable 3,895,524,304.35 3,988,878,234.03
Accounts received in advance 17,569,538.10 40,339,905.63
Selling financial asset of
repurchase
Commission charge and
16
国药集团一致药业股份有限公司 2015 年第一季度报告全文
commission payable
Wage payable 102,798,856.26 171,958,142.88
Taxes payable 111,589,593.99 77,445,669.46
Interest payable 10,700,617.28 6,666,712.19
Dividend payable
Other accounts payable 367,743,030.24 412,347,201.51
Reinsurance payables
Insurance contract reserve
Security trading of agency
Security sales of agency
Divided into liability held for sale
Non-current liabilities due within 1
5,260,000.00 4,000,000.00
year
Other current liabilities
Total current liabilities 8,049,195,742.75 7,687,757,035.22
Non-current liabilities:
Long-term loans 47,351,573.85 39,695,448.00
Bonds payable
Including: preferred stock
Perpetual capital
securities
Long-term account payable
Long-term wages payable 2,896,000.00 2,896,000.00
Special accounts payable 1,287,000.00 1,287,000.00
Projected liabilities
Deferred income 174,529,601.70 176,366,201.15
Deferred income tax liabilities 23,767,710.79 24,297,076.57
Other non-current liabilities 45,427,343.31 45,427,343.31
Total non-current liabilities 295,259,229.65 289,969,069.03
Total liabilities 8,344,454,972.40 7,977,726,104.25
Owner’s equity:
Share capital 362,631,943.00 362,631,943.00
Other equity instrument
Including: preferred stock
Perpetual capital
securities
17
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Capital public reserve 1,863,894,533.34 1,863,894,533.34
Less: Inventory shares
Other comprehensive income
Reasonable reserve
Surplus public reserve 181,315,971.50 181,315,971.50
Provision of general risk
Retained profit 2,553,791,612.07 2,356,765,374.25
Total owner’s equity attributable to
4,961,634,059.91 4,764,607,822.09
parent company
Minority interests 93,172,869.04 86,607,614.56
Total owner’s equity 5,054,806,928.95 4,851,215,436.65
Total liabilities and owner’s equity 13,399,261,901.35 12,828,941,540.90
Legal Representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institute: Zhou Feifei
2. Balance Sheet of Parent Company
In RMB
Item Closing balance Opening balance
Current assets:
Monetary funds 224,476,789.36 257,173,314.81
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes receivable 4,826,619.30 47,389,669.59
Accounts receivable 599,365,937.37 513,791,982.48
Account paid in advance 3,720,376.61 5,047,755.80
Interest receivable 1,886,079.13 1,890,165.10
Dividends receivable
Other receivables 1,142,166,550.88 1,111,423,809.76
Inventories 161,098,976.95 184,880,147.05
Divided into assets held for sale
Non-current assets maturing within
one year
Other current assets 39,482.38 2,560,096.51
Total current assets 2,137,580,811.98 2,124,156,941.10
18
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Non-current assets:
Available-for-sale financial assets
Held-to-maturity investments
Long-term receivables
Long-term equity investments 2,784,714,188.34 2,772,004,341.23
Investment property 4,985,769.90 5,272,980.96
Fixed assets 16,441,771.27 17,175,509.65
Construction in progress 321,855,843.98 299,290,846.13
Project materials
Disposal of fixed assets
Productive biological assets
Oil and natural gas assets
Intangible assets 36,530,494.15 36,923,545.12
Research and development costs
Goodwill
Long-term deferred expenses 5,404,665.63 5,681,186.10
Deferred income tax assets 2,800,803.02 2,800,803.02
Other non-current assets 61,633,726.33 68,103,087.93
Total non-current assets 3,234,367,262.62 3,207,252,300.14
Total assets 5,371,948,074.60 5,331,409,241.24
Current liabilities:
Short-term borrowings 300,000,000.00 202,000,000.00
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes payable 172,640,734.42 274,584,574.89
Accounts payable 357,192,001.76 314,477,971.19
Accounts received in advance 292,420.06 322,008.81
Wage payable 14,504,526.83 20,339,767.52
Taxes payable 17,628,327.90 13,695,533.72
Interest payable 172,307.47 86,831.07
Dividend payable
Other accounts payable 413,869,192.67 447,928,781.45
19
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Divided into liability held for sale
Non-current liabilities due within 1
year
Other current liabilities
Total current liabilities 1,276,299,511.11 1,273,435,468.65
Non-current liabilities:
Long-term loans 47,351,573.85 39,695,448.00
Bonds payable
Including: preferred stock
Perpetual capital
securities
Long-term account payable
Long-term wages payable 226,000.00 226,000.00
Special accounts payable 800,000.00 800,000.00
Projected liabilities
Deferred income 5,000,000.00 5,000,000.00
Deferred income tax liabilities 3,773,319.00 3,773,319.00
Other non-current liabilities
Total non-current liabilities 57,150,892.85 49,494,767.00
Total liabilities 1,333,450,403.96 1,322,930,235.65
Owners’ equity:
Share capita 362,631,943.00 362,631,943.00
Other equity instrument
Including: preferred stock
Perpetual capital
securities
Capital public reserve 1,869,692,921.70 1,869,692,921.70
Less: Inventory shares
Other comprehensive income
Reasonable reserve
Surplus reserve 181,315,971.50 181,315,971.50
Retained profit 1,624,856,834.44 1,594,838,169.39
Total owner’s equity 4,038,497,670.64 4,008,479,005.59
Total liabilities and owner’s equity 5,371,948,074.60 5,331,409,241.24
20
国药集团一致药业股份有限公司 2015 年第一季度报告全文
3. Consolidated Profit Statement
In RMB
Item Current Period Last Period
I. Total operating income 6,261,714,700.23 5,533,524,159.08
Including: Operating income 6,261,714,700.23 5,533,524,159.08
Interest income
Insurance gained
Commission charge and commission
income
II. Total operating cost 6,022,798,273.95 5,333,488,597.29
Including: Operating cost 5,727,401,760.21 5,029,648,506.06
Interest expense
Commission charge and commission
expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Operating tax and extras 13,110,911.30 16,456,412.89
Sales expenses 149,553,656.91 140,963,077.19
Administration expenses 101,713,713.18 96,697,790.30
Financial expenses 27,144,103.26 47,251,787.11
Losses of devaluation of asset 3,874,129.09 2,471,023.74
Add: Changing income of fair
value(Loss is listed with ―-‖)
Investment income (Loss is listed
12,709,847.11 10,759,866.17
with ―-‖)
Including: Investment income on
12,709,847.11 10,759,866.17
affiliated company and joint venture
Exchange income (Loss is listed
with ―-‖)
III. Operating profit (Loss is listed with
251,626,273.39 210,795,427.96
―-‖)
21
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Add: Non-operating income 5,960,690.37 3,794,783.96
Including: Disposal gains of
2,827.43 87,847.28
non-current asset
Less: Non-operating expense 323,927.54 392,320.33
Including: Disposal loss of
121,498.58 37,633.78
non-current asset
IV. Total Profit (Loss is listed with ―-‖) 257,263,036.22 214,197,891.59
Less: Income tax expense 55,141,543.92 42,222,561.34
V. Net profit (Net loss is listed with ―-‖) 202,121,492.30 171,975,330.25
Net profit attributable to owner’s of
197,026,237.82 167,818,387.39
parent company
Minority shareholders’ gains and
5,095,254.48 4,156,942.86
losses
VI. Net after-tax of other comprehensive
income
Net after-tax of other comprehensive
income attributable to owners of parent
company
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1. Changes as a result of
re-measurement of net defined benefit
plan liability or asset
2. Share of the other
comprehensive income of the investee
accounted for using equity method which
will not be reclassified subsequently to
profit and loss
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1. Share of the other
comprehensive income of the investee
accounted for using equity method which
will be reclassified subsequently to profit
or loss
2. Gains or losses arising
from changes in fair value of
available-for-sale financial assets
22
国药集团一致药业股份有限公司 2015 年第一季度报告全文
3. Gains or losses arising
from reclassification of held-to-maturity
investment as available-for-sale financial
assets
4. The effect hedging portion
of gains or losses arising from cash flow
hedging instruments
5. Translation differences
arising on translation of foreign currency
financial statements
6. Other
Net after-tax of other comprehensive
income attributable to minority
shareholders
VII. Total comprehensive income 202,121,492.30 171,975,330.25
Total comprehensive income
197,026,237.82 167,818,387.39
attributable to owners of parent Company
Total comprehensive income
5,095,254.48 4,156,942.86
attributable to minority shareholders
VIII. Earnings per share:
(i) Basic earnings per share 0.543 0.582
(ii) Diluted earnings per share 0.543 0.582
Enterprise combine under the same control in the Period, the combined party realized net profit of 0 Yuan before combination, and
realized 0 Yuan at last period for combined party
Legal Representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institute: Zhou Feifei
4. Profit Statement of Parent Company
In RMB
Item Current Period Last Period
I. Operating income 682,110,778.60 630,928,100.07
Less: Operating cost 651,556,733.03 606,916,889.78
Operating tax and extras 1,291,426.07 1,448,928.34
Sales expenses 11,197,849.92 10,773,372.91
Administration expenses 10,188,227.73 10,935,015.93
Financial expenses -15,344,108.10 -825,878.75
Losses of devaluation of asset 142,228.63 202,141.81
23
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Add: Changing income of fair
value(Loss is listed with ―-‖)
Investment income (Loss is
12,709,847.11 10,759,866.17
listed with ―-‖)
Including: Investment income
12,709,847.11 10,759,866.17
on affiliated company and joint venture
II. Operating profit (Loss is listed
35,788,268.43 12,237,496.22
with ―-‖)
Add: Non-operating income 2.62 68,960.33
Including: Disposal gains of
non-current asset
Less: Non-operating expense 0.01
Including: Disposal loss of
non-current asset
III. Total Profit (Loss is listed with
35,788,271.04 12,306,456.55
―-‖)
Less: Income tax expense 5,769,605.99 386,647.60
IV. Net profit (Net loss is listed with
30,018,665.05 11,919,808.95
―-‖)
V. Net after-tax of other comprehensive
income
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1. Changes as a result of
re-measurement of net defined benefit
plan liability or asset
2. Share of the other
comprehensive income of the investee
accounted for using equity method
which will not be reclassified
subsequently to profit and loss
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1. Share of the other
comprehensive income of the investee
accounted for using equity method
which will be reclassified subsequently
to profit or loss
24
国药集团一致药业股份有限公司 2015 年第一季度报告全文
2. Gains or losses arising
from changes in fair value of
available-for-sale financial assets
3. Gains or losses arising
from reclassification of held-to-maturity
investment as available-for-sale
financial assets
4. The effect hedging
portion of gains or losses arising from
cash flow hedging instruments
5. Translation differences
arising on translation of foreign
currency financial statements
6. Other
VI. Total comprehensive income 30,018,665.05 11,919,808.95
VII. Earnings per share:
(i) Basic earnings per share
(ii) Diluted earnings per share
5. Consolidated Cash Flow Statement
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor 6,225,835,431.92 5,724,848,719.86
services
Net increase of customer deposit
and interbank deposit
Net increase of loan from central
bank
Net increase of capital borrowed
from other financial institution
Cash received from original
insurance contract fee
Net cash received from reinsurance
business
Net increase of insured savings and
25
国药集团一致药业股份有限公司 2015 年第一季度报告全文
investment
Net increase of amount from
disposal financial assets that measured
by fair value and with variation
reckoned into current gains/losses
Cash received from interest,
commission charge and commission
Net increase of capital borrowed
Net increase of returned business
capital
Write-back of tax received 333,471.38 458,279.02
Other cash received concerning
29,217,661.76 14,374,722.13
operating activities
Subtotal of cash inflow arising from
6,255,386,565.06 5,739,681,721.01
operating activities
Cash paid for purchasing
commodities and receiving labor 5,644,089,272.34 5,702,098,302.24
service
Net increase of customer loans
and advances
Net increase of deposits in central
bank and interbank
Cash paid for original insurance
contract compensation
Cash paid for interest, commission
charge and commission
Cash paid for bonus of guarantee
slip
Cash paid to/for staff and workers 215,442,209.33 200,359,447.38
Taxes paid 132,719,577.58 172,863,504.48
Other cash paid concerning
90,043,632.87
operating activities 80,955,899.11
Subtotal of cash outflow arising from
6,165,364,886.97
operating activities 6,073,206,958.36
Net cash flows arising from operating
-425,683,165.96
activities 182,179,606.70
II. Cash flows arising from investing
activities:
Cash received from recovering
26
国药集团一致药业股份有限公司 2015 年第一季度报告全文
investment
Cash received from investment
income
Net cash received from disposal of
fixed, intangible and other long-term 22,330.68 252,600.00
assets
Net cash received from disposal of
subsidiaries and other units
Other cash received concerning
0.00 5,080,588.84
investing activities
Subtotal of cash inflow from investing
22,330.68 5,333,188.84
activities
Cash paid for purchasing fixed,
49,381,727.56 45,663,080.22
intangible and other long-term assets
Cash paid for investment
Net increase of mortgaged loans
Net cash received from
subsidiaries and other units obtained
Other cash paid concerning
252,000.00
investing activities
Subtotal of cash outflow from investing
49,633,727.56 45,663,080.22
activities
Net cash flows arising from investing
-49,611,396.88 -40,329,891.38
activities
III. Cash flows arising from financing
activities
Cash received from absorbing
1,470,000.00 1,941,759,896.01
investment
Including: Cash received from
absorbing minority shareholders’ 1,470,000.00
investment by subsidiaries
Cash received from loans 186,993,124.89
Cash received from issuing bonds
Other cash received concerning
financing activities
Subtotal of cash inflow from financing
1,470,000.00 2,128,753,020.90
activities
Cash paid for settling debts 63,839,764.78 447,290,917.24
27
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Cash paid for dividend and profit
25,275,601.52 48,547,024.91
distributing or interest paying
Including: Dividend and profit of
minority shareholder paid by
subsidiaries
Other cash paid concerning
29,012,559.76 21,072,437.76
financing activities
Subtotal of cash outflow from 118,127,926.06 516,910,379.91
financing activities
Net cash flows arising from financing
-116,428,354.06 1,611,842,640.99
activities
IV. Influence on cash and cash
equivalents due to fluctuation in 9,250.41 4,636.82
exchange rate
V. Net increase of cash and cash
15,919,534.17 1,145,834,220.47
equivalents
Add: Balance of cash and cash
854,212,006.84 1,097,948,354.45
equivalents at the period -begin
VI. Balance of cash and cash
870,131,541.01 2,243,782,574.92
equivalents at the period -end
6. Cash Flow Statement of Parent Company
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor 711,445,698.87 750,568,332.49
services
Write-back of tax received
Other cash received concerning
3,324,178.44 3,210,375.82
operating activities
Subtotal of cash inflow arising from
714,769,877.31 753,778,708.31
operating activities
Cash paid for purchasing
commodities and receiving labor 697,915,966.60 765,087,858.27
service
Cash paid to/for staff and workers 18,182,948.12 15,533,624.52
28
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Taxes paid 6,338,325.38 2,462,773.93
Other cash paid concerning
8,502,230.29 5,047,627.07
operating activities
Subtotal of cash outflow arising from
730,939,470.39 788,131,883.79
operating activities
Net cash flows arising from operating
-16,169,593.08 -34,353,175.48
activities
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from investment
15,334,120.54 15,446,654.64
income
Net cash received from disposal of
fixed, intangible and other long-term
assets
Net cash received from disposal of
subsidiaries and other units
Other cash received concerning
735,380,315.47 904,600,000.00
investing activities
Subtotal of cash inflow from investing
750,714,436.01 920,046,654.64
activities
Cash paid for purchasing fixed,
43,164,474.15 17,326,293.40
intangible and other long-term assets
Cash paid for investment
Net cash received from
subsidiaries and other units
Other cash paid concerning
765,721,572.00 1,341,643,308.59
investing activities
Subtotal of cash outflow from investing
808,886,046.15 1,358,969,601.99
activities
Net cash flows arising from investing
-58,171,610.14 -438,922,947.35
activities
III. Cash flows arising from financing
activities
Cash received from absorbing
1,941,759,896.01
investment
Cash received from loans 57,656,125.85 50,000,000.00
29
国药集团一致药业股份有限公司 2015 年第一季度报告全文
Cash received from issuing bonds
Other cash received concerning
56,300,000.00
financing activities
Subtotal of cash inflow from financing
57,656,125.85 2,048,059,896.01
activities
Cash paid for settling debts 10,000,000.00 395,000,000.00
Cash paid for dividend and profit
4,011,288.08 16,123,526.33
distributing or interest paying
Other cash paid concerning
2,000,160.00 12,544,637.52
financing activities
Subtotal of cash outflow from
16,011,448.08 423,668,163.85
financing activities
Net cash flows arising from financing
41,644,677.77 1,624,391,732.16
activities
IV. Influence on cash and cash
equivalents due to fluctuation in
exchange rate
V. Net increase of cash and cash
-32,696,525.45 1,151,115,609.33
equivalents
Add: Balance of cash and cash
257,173,314.81 218,342,947.03
equivalents at the period -begin
VI. Balance of cash and cash
224,476,789.36 1,369,458,556.36
equivalents at the period -end
II. Audit report
Whether the first quarterly report had been audited or not
□ Yes √ No
The first quarterly report of the Company had not been audited.
30
